Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
Open accessAbstract
Very little is known about the comparative long-term effectiveness of novel antipsychotics in relapse prevention, especially in first-episode schizophrenia. Nationwide data from Finnish health care registers were gathered prospectively for all persons with periods of inpatient care due to schizophrenia in Finland during 1972-2014. Altogether 62250 persons were included in the prevalent cohort, and 8719 in the incident (first-episode schizophrenia) cohort. The follow-up for antipsychotic use started at 1996 for the prevalent cohort, and at the first discharge from inpatient care for the incident cases. Within-individual Cox regression models for risk of psychiatric and all-cause hospitalization were constructed to compare risk during antipsychotic use and no use using individual as his/her own control to eliminate selection bias. With follow-up time up to 20 years (median = 14.1, interquartile range = 6.9-20.0), 59% of the prevalent cohort were readmitted to psychiatric inpatient care. Olanzapine long-acting injection (LAI; adjusted hazard ratio = 0.46, 95% confidence interval = 0.36-0.61), clozapine (0.51, 0.49-0.53), and paliperidone LAI (0.51, 0.40-0.66) were associated with the lowest risk of psychiatric rehospitalization in the prevalent cohort. Among first-episode patients, the lowest risks were observed for flupentixol LAI (0.24, 0.12-0.49), olanzapine LAI (0.26, 0.16-0.44), and perphenazine LAI (0.39, 0.31-0.50). Clozapine and LAIs were associated with the lowest risk of all-cause hospitalization in both cohorts. Clozapine and LAIs are the most effective treatments in preventing psychiatric and all-cause hospitalization among chronic and first-episode patients with schizophrenia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In addition to the benefits of reduced treatment gaps with LAI versus oral antipsychotics, studies, particularly those in real-world samples, have demonstrated reduced psychopathology, relapses, hospitalizations, and mortality risk with LAI formulations.
“In addition to the benefits of reduced treatment gaps with LAI versus oral antipsychotics, studies, particularly those in real-world samples, have demonstrated reduced psychopathology, relapses, hospitalizations, and mortality risk with LAI formulations [98–104].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [102]
The Results (Oral Vs LAI Comparisons) and Discussion report lower psychiatric and all-cause hospitalization risk during LAI use than oral antipsychotic use in this real-world schizophrenia cohort. Psychiatric rehospitalization is relevant to relapse, but the Discussion says the study’s outcomes were limited to hospitalization; it does not establish reduced psychopathology or mortality risk with LAIs. The mortality statement in the Discussion concerns clozapine, not LAIs. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredBoth the clinical benefits and cost-effectiveness of the DPP lifestyle interventions was maintained over a 10-year follow up, even when compared to metformin as a control condition.
“Furthermore, both the clinical benefits and cost-effectiveness of the DPP lifestyle interventions was maintained over a 10-year follow up, even when compared to metformin as a control condition.234,235”
From The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness (2019) · cites this paper as [234]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · see citing works
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · see citing works
Self-citationTiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670 · see citing works
Self-citationTiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619 · see citing works
Self-citationTiihonen, J., Wahlbeck, K., Lönnqvist, J. K., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. K. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 385 · see citing works
Self-citationFrom prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
Tanskanen, A. J., Taipale, H. T., Koponen, M., Tolppanen, A., Hartikainen, S. A., Ahonen, R. S., & Tiihonen, J. (2015) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-015-0140-z · Cited by 200 · see citing works
Self-citationThe Societal Cost of Schizophrenia: A Systematic Review
Jin, H., & Mosweu, I. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0444-6 · Cited by 195 · see citing works
Decline in the Incidence of Schizophrenia in Finnish Cohorts Born From 1954 to 1965
Suvisaari, J., Haukka, J. K., Tanskanen, A. J., & Lönnqvist, J. K. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.733 · Cited by 148 · see citing works
Self-citationHayes, R. D., Downs, J. M., Chang, C., Jackson, R., Shetty, H., Broadbent, M., Hotopf, M. H., & Stewart, R. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu120 · Cited by 129 · see citing works
Selection Bias in Clinical Trials With Antipsychotics
Hofer, A., Hummer, M., Huber, R., Kurz, M., Walch, T., & Fleischhacker, W. W. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00019 · Cited by 112 · see citing works
Fitzsimons, J., Berk, M., Lambert, T., Bourin, M., & Dodd, S. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.4.731 · Cited by 80 · see citing works
Kiviniemi, M., Suvisaari, J., Koivumaa-Honkanen, H. T., Häkkinen, U., Isohanni, M. K., & Hakko, H. H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.043 · Cited by 77 · see citing works
Taipale, H. T., Tanskanen, A. J., Koponen, M., Tolppanen, A., Tiihonen, J., & Hartikainen, S. A. (2016) · Clinical Epidemiology · doi:10.2147/clep.s116160 · Cited by 73 · see citing works
Self-citationVanasse, A., Blais, L., Courteau, J., Cohen, A. A., Roberge, P., Larouche, A., Grignon, S., Fleury, M., LESAGE, A. D., Demers, M., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12621 · Cited by 70 · see citing works
Kühl, J. O. G., Laursen, T. M., Thorup, A. A. E., & Nordentoft, M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.023 · Cited by 59 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531 · see citing works
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 607 · see citing works
Taipale, H., Tanskanen, A., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tiihonen, J. (2020) · World Psychiatry · doi:10.1002/wps.20699 · Cited by 415 · see citing works
Self-citationKishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369 · see citing works
Tiihonen, J., Taipale, H. T., Mehtälä, J., Vattulainen, P., Correll, C. U., & Tanskanen, A. J. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4320 · Cited by 297 · see citing works
Self-citationCorrell, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205 · see citing works
The clinical course of schizophrenia in women and men—a nation-wide cohort study
Sommer, I. E., Tiihonen, J., van Mourik, A., Tanskanen, A. J., & Taipale, H. T. (2020) · Schizophrenia · doi:10.1038/s41537-020-0102-z · Cited by 179 · see citing works
Self-citationAntipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Lähteenvuo, M., & Tiihonen, J. (2021) · Drugs · doi:10.1007/s40265-021-01556-4 · Cited by 156 · see citing works
Self-citationMortality in schizophrenia: 30-year nationwide follow-up study
Tanskanen, A., Tiihonen, J., & Taipale, H. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12913 · Cited by 134 · see citing works
Self-citationTaipale, H., Schneider-Thoma, J., Pinzón-Espinosa, J., Radua, J., Efthimiou, O., Vinkers, C. H., Mittendorfer-Rutz, E., Cardoner, N., Pintor, L., Tanskanen, A., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.3990 · Cited by 129 · see citing works
Self-citationOstuzzi, G., Bertolini, F., Tedeschi, F., Vita, G., Brambilla, P., Fabro, L., Gastaldon, C., Papola, D., Purgato, M., Nosari, G., et al. (2022) · World Psychiatry · doi:10.1002/wps.20972 · Cited by 119 · see citing works
Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117 · see citing works
Wang, G., Zheng, W., Li, X.-B., Wang, S.-B., Cai, D.-B., Yang, X.-H., Ungvari, G. S., Xiang, Y., & Correll, C. U. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.08.002 · Cited by 108 · see citing works
Taipale, H., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa111 · Cited by 85 · see citing works
Self-citationOstuzzi, G., Bertolini, F., Giovane, C. D., Tedeschi, F., Bovo, C., Gastaldon, C., Nosè, M., Ogheri, F., Papola, D., Purgato, M., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20071120 · Cited by 83 · see citing works
Solmi, M., Tiihonen, J., Lähteenvuo, M., Tanskanen, A. J., Correll, C. U., & Taipale, H. T. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab087 · Cited by 82 · see citing works
Self-citationMorbidity and mortality in schizophrenia with comorbid substance use disorders
Lähteenvuo, M., Batalla, A., Luykx, J. J., Mittendorfer‐Rutz, E., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13291 · Cited by 78 · see citing works
Self-citationKane, J., Mcevoy, J., Correll, C., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 74 · see citing works
Clozapine resistant schizophrenia: Newer avenues of management
Chakrabarti, S. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i8.429 · Cited by 74 · see citing works
Treatment resistant schizophrenia – review and a call to action
Lally, J., & Gaughran, F. (2018) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2018.47 · Cited by 61 · see citing works
Veronese, M., Santangelo, B., Jauhar, S., D’Ambrosio, E., Demjaha, A., Salimbeni, H., Jin, H., McCrone, P., Turkheimer, F., & Howes, O. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00866-7 · Cited by 58 · see citing works
Correll, C. U., Brevig, T., & Brain, C. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2318-x · Cited by 55 · see citing works
Lindenmayer, J., Glick, I. D., Talreja, H., & Underriner, M. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001225 · Cited by 53 · see citing works
Luykx, J. J., Stam, N., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2019.267 · Cited by 53 · see citing works
Self-citationLong-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P., & Correll, C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 53 · see citing works
Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review
Lian, L., Kim, D. D., Procyshyn, R. M., Cázares, D., Honer, W. G., & Barr, A. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267808 · Cited by 49 · see citing works
Lian, L., Kim, D. D., Procyshyn, R. M., Fredrikson, D. H., Cázares, D., Honer, W. G., & Barr, A. M. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13202 · Cited by 47 · see citing works
Shah, A., Xie, L., Kariburyo, F., Zhang, Q., & Gore, M. R. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0786-x · Cited by 47 · see citing works
Factors and their weight in reducing life expectancy in schizophrenia
Correll, C. U., Bitter, I., Hoti, F. J., Mehtälä, J., Wooller, A., Pungor, K., & Tiihonen, J. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.10.019 · Cited by 44 · see citing works
Self-citationAbdel‐Baki, A., Thibault, D., Medrano, S., Stip, É., Ladouceur, M., Tahir, M. R., & Potvin, S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12826 · Cited by 39 · see citing works
Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
Lintunen, J., Lähteenvuo, M., Tiihonen, J., Tanskanen, A. J., & Taipale, H. T. (2021) · Schizophrenia · doi:10.1038/s41537-020-00135-y · Cited by 39 · see citing works
Self-citationLin, C., Chen, F.-C., Chan, H., & Hsu, C. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz035 · Cited by 38 · see citing works
Effect of Valproic Acid on the Metabolic Spectrum of Clozapine in Patients With Schizophrenia
Smith, R. L., Wollmann, B. M., Kyllesø, L., Tran, T. T. A., Tveito, M., & Molden, E. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001507 · Cited by 37 · see citing works
Okoli, C. T. C., Kappi, A. A., Wang, T., Makowski, A., & Cooley, A. T. (2021) · International Journal of Mental Health Nursing · doi:10.1111/inm.12964 · Cited by 36 · see citing works
Daod, E., Krivoy, A., Shoval, G., Zubedat, S., Lally, J., Vadas, L., Weizman, A., Reshef, A., & Bloch, B. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.03.029 · Cited by 36 · see citing works
An international research agenda for clozapine-resistant schizophrenia
Luykx, J. J., González-Díaz, J. M., Guu, T., van der Horst, M. Z., van Dellen, E., Boks, M. P., Gülöksüz, S., DeLisi, L. E., Sommer, I. E., Cummins, R., et al. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00109-8 · Cited by 34 · see citing works
Self-citationComparative Effectiveness of Antipsychotics in Patients With Schizophrenia Spectrum Disorder
Hamina, A., Taipale, H. T., Lieslehto, J., Lähteenvuo, M., Tanskanen, A. J., Mittendorfer‐Rutz, E., & Tiihonen, J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.38358 · Cited by 32 · see citing works
Self-citationAntipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
Taipale, H. T., Puranen, A., Mittendorfer‐Rutz, E., Tiihonen, J., Tanskanen, A. J., Červenka, S., & Lähteenvuo, M. (2020) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1854853 · Cited by 31 · see citing works
Self-citationBhavsar, V., Kosidou, K., Widman, L., Orsini, N., Hodsoll, J. P., Dalman, C., & MacCabe, J. H. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz055 · Cited by 31 · see citing works
Miranda, J. J. F., Díaz-Fernández, S., Berardis, D. D., & Lopez-Munoz, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071408 · Cited by 30 · see citing works
Leijala, J., Kampman, O., Suvisaari, J., & Eskelinen, S. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03037-0 · Cited by 29 · see citing works
Takács, P., Czobor, P., Fehér, L., Gimesi-Országh, J., Fadgyas‐Freyler, P., Bacskai, M., Rakonczai, P., Borsi, A., Hegyi, R., Németh, T., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218071 · Cited by 28 · see citing works
Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
Lintunen, J., Taipale, H. T., Tanskanen, A. J., Mittendorfer‐Rutz, E., Tiihonen, J., & Lähteenvuo, M. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab004 · Cited by 28 · see citing works
Self-citationKim, S., Kim, S., Koh, M., Choi, G., Kim, J.-J., Paik, I., Kim, S., Choi, Y. S., Lee, Y. H., Suh, J., et al. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13446 · Cited by 27 · see citing works
Weiser, M., Davis, J. M., Brown, C. H., Slade, E. P., Fang, L., Medoff, D. R., Buchanan, R. W., Levi, L. W., Davidson, M., & Kreyenbuhl, J. A. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111657 · Cited by 24 · see citing works
Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
Cuevas, C. D. L., Sanz, E. J., & de León, J. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s495254 · Cited by 22 · see citing works
Lin, Y., Wu, C., Liu, C., Kuo, P., Chan, H., & Chen, W. J. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac046 · Cited by 22 · see citing works
Schwartz, S. E., Carilli, C., Mian, T., Ruekert, L., & Kumar, A. (2022) · Mental Health Clinician · doi:10.9740/mhc.2022.08.232 · Cited by 22 · see citing works
Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review
Álamo, C. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02299-8 · Cited by 23 · see citing works
What is schizophrenia – symptomatology
Striebel, J. M. (2024) · CNS Spectrums · doi:10.1017/s1092852924000622 · Cited by 21 · see citing works
Nielsen, R. E., Hessellund, K. B., Valentin, J. B., & Licht, R. W. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.07.020 · Cited by 21 · see citing works
Tveito, M., Smith, R. L., Molden, E., Haslemo, T., Refsum, H., Hartberg, C. B., Correll, C. U., & Høiseth, G. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000961 · Cited by 21 · see citing works
Mahlich, J., Olbrich, K., Wilk, A., Wimmer, A., & Wolff‐Menzler, C. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00900-y · Cited by 21 · see citing works
Faden, J., Ramirez, C., Martinez, V., & Citrome, L. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2370349 · Cited by 20 · see citing works
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02488-1 · Cited by 19 · see citing works
Tveito, M., Molden, E., Høiseth, G., Correll, C. U., & Smith, R. L. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02768-0 · Cited by 19 · see citing works
General and violent recidivism of former forensic psychiatric patients in Finland
Ojansuu, I., Latvala, A., Kautiainen, H., Forsman, J., Tiihonen, J., & Lähteenvuo, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1157171 · Cited by 17 · see citing works
Self-citationThe Effect of Valproic Acid on Olanzapine Serum Concentration
Tveito, M., Smith, R. L., Høiseth, G., & Molden, E. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001126 · Cited by 17 · see citing works
Taipale, H. T., Lieslehto, J., Lähteenvuo, M., Hamina, A., Tanskanen, A., Mittendorfer‐Rutz, E., Paljärvi, T., Solmi, M., Cipriani, A., Correll, C. U., et al. (2024) · World Psychiatry · doi:10.1002/wps.21205 · Cited by 16 · see citing works
Self-citationLi, P., Benson, C. J., Geng, Z., Seo, S., Patel, C. A., & Doshi, J. A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2189859 · Cited by 16 · see citing works
Antipsychotiques à Action Prolongée: Révision de l’algorithme QAAPAPLE
Stip, É., Abdel‐Baki, A., Roy, M., Bloom, D., & Grignon, S. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719847193 · Cited by 16 · see citing works
Joo, S. W., Shon, S., Choi, G., Koh, M., Cho, S. W., & Lee, J. S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.138 · Cited by 16 · see citing works
Joo, S. W., Kim, H., Jo, Y. T., Ahn, S., Choi, Y. J., Choi, W., Park, S., & Lee, J. S. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.03.010 · Cited by 15 · see citing works
Depot/Long Acting Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
Özgüven, H. D., & Kır, Y. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27480 · Cited by 14 · see citing works
Smith, R. L., Tveito, M., Kyllesø, L., Jukić, M. M., Ingelman‐Sundberg, M., Andreassen, O. A., & Molden, E. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.025 · Cited by 14 · see citing works
Tost, M., González-Rodríguez, A., Aguayo, R., Pedrero, A. Á., Montalvo, I., Barbero, J. D., Gabernet, R., Izquierdo, E., Merodio, I., Monreal, J. A., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110619 · Cited by 14 · see citing works
Pappa, S., Barnett, J., & Mason, K. (2022) · CNS Drugs · doi:10.1007/s40263-022-00976-4 · Cited by 14 · see citing works
Suicidal Behavior and Medication Adherence in Schizophrenic Patients
Warriach, Z. I., Sanchez‐Gonzalez, M. A., & Ferrer, G. F. (2021) · Cureus · doi:10.7759/cureus.12473 · Cited by 13 · see citing works
Strømme, M. F., Mellesdal, L. S., Bartz-Johannesen, C. A., Kroken, R. A., Krogenes, M. L., Mehlum, L., & Johnsen, E. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001497 · Cited by 13 · see citing works
Hodson, N., Majid, M., Vlaev, I., & Singh, S. P. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059526 · Cited by 13 · see citing works
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071101 · Cited by 13 · see citing works
García-Carmona, J. A., Barnett, J., Campos-Navarro, M. P., Mason, K., Valdivia-Muñoz, F., & Pappa, S. (2022) · Neuroscience Applied · doi:10.1016/j.nsa.2022.100111 · Cited by 12 · see citing works
Li, P., Geng, Z., Benson, C. J., Patel, C. A., & Doshi, J. A. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03075-6 · Cited by 12 · see citing works
Strømme, M. F., Mellesdal, L., Bartz-Johannessen, C., Kroken, R. A., Krogenes, M. L., Mehlum, L. I., & Johnsen, E. (2022) · NORA - Norwegian Open Research Archives · Cited by 12 · see citing works
Catalán, A., García, L., Sánchez-Alonso, S., Gil, P., Díaz‐Marsá, M., Olivares, J. M., Baltanás, T. R., Pérez‐Martín, J., Torres, M. Á. G., Ovejero, S., et al. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13098 · Cited by 12 · see citing works
Oral Versus Long-Acting Injectable Antipsychotic Treatment for People With Severe Schizophrenia
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2021) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001299 · Cited by 12 · see citing works
Li, Q., Li, X. R., Ye, C., Jia, M., & Si, T. (2023) · CNS Drugs · doi:10.1007/s40263-023-01028-1 · Cited by 12 · see citing works
Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia
Hamina, A., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2020) · Medical Care · doi:10.1097/mlr.0000000000001369 · Cited by 11 · see citing works
Self-citationDoes antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?
Faden, J., Kiryankova-Dalseth, N., Barghini, R., & Citrome, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1847274 · Cited by 11 · see citing works
Liu, J., Wang, Q., Su, L., Yang, L., Zou, L., & Bai, L. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03728-2 · Cited by 11 · see citing works
Giron‐Hernandez, C., Han, J. H., Alberio, R., Singh, A., García‐Portilla, M. P., Pompili, M., Knight, R. K., Richarz, U., Gopal, S., & Antunes, J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s400342 · Cited by 10 · see citing works
Patel, R. S., & Tankersley, W. E. (2021) · CNS Spectrums · doi:10.1017/s109285292100050x · Cited by 10 · see citing works
Doshi, J. A., Li, P., Geng, Z., Seo, S., Patel, C. A., & Benson, C. J. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20230142 · Cited by 9 · see citing works
Preventing disease progression in schizophrenia: What are we waiting for
Lieberman, J. A., Mendelsohn, A. I., Goldberg, T. E., & Emsley, R. A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.12.042 · Cited by 9 · see citing works
Joo, S. W., Kim, H., Jo, Y. T., Choi, Y. J., Ahn, S., & Lee, J. S. (2021) · Psychological Medicine · doi:10.1017/s0033291721001379 · Cited by 9 · see citing works
Brodeur, S., Vanasse, A., Courteau, J., Stip, É., LESAGE, A. D., Fleury, M., Courteau, M., & Roy, M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13413 · Cited by 9 · see citing works
Baune, B. T. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2287612 · Cited by 10 · see citing works
Suetani, S., Siskind, D. J., Phillipou, A., Waterreus, A. J., Morgan, V. A., & Castle, D. J. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674211009602 · Cited by 9 · see citing works
Miranda, J. J. F., Díaz-Fernández, S., & Lopez-Munoz, F. J. (2022) · Biomedicines · doi:10.3390/biomedicines11010042 · Cited by 9 · see citing works
Tveito, M., Høiseth, G., Haslemo, T., Molden, E., & Smith, R. L. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03114-z · Cited by 9 · see citing works
Aguglia, A., Fusar‐Poli, L., Amerio, A., Placenti, V., Concerto, C., Martinotti, G., Carrà, G., Bartoli, F., D’Agostino, A., Serafini, G., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.784366 · Cited by 8 · see citing works
Üçok, A., Yağcıoğlu, E. A., Aydin, M., Kara, İ., Erbasan, V., Türkoğlu, Ö., Ergün, S., Chousein, M., Oktar, N., Ucar, N., et al. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000348 · Cited by 8 · see citing works
Díaz-Fernández, S., López-Muñoz, F., & Fernández-Miranda, J. J. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000581 · Cited by 8 · see citing works
Erickson, B., Ehrie, J., Murray, S., Dougherty, R. J., Wainberg, M. L., Dixon, L. B., & Goldman, M. L. (2022) · Psychiatric Services · doi:10.1176/appi.ps.20220196 · Cited by 8 · see citing works
Schmidt-Kraepelin, C., Feyerabend, S., Engelke, C., Riesbeck, M., Meisenzahl‐Lechner, E., Gäebel, W., Verde, P.-E., Kolbe, H., Correll, C. U., Leucht, S., et al. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01063-4 · Cited by 8 · see citing works
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 8 · see citing works
Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan
Ballon, J. S., Kahn, R. S., Arevalo, C., Dunbar, M., McDonnell, D., & Correll, C. U. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15511 · Cited by 7 · see citing works
Chan, H., Huang, C.-Y., & Yen, Y. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03513-7 · Cited by 7 · see citing works
Cristarella, T., Castillon, G., Nepveu, J.-F., & Moride, Y. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.915 · Cited by 7 · see citing works
Hattori, S., Suda, A., Kishida, I., Miyauchi, M., Shiraishi, Y., Noguchi, N., Furuno, T., Asami, T., Fujibayashi, M., Tsujita, N., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04617-y · Cited by 7 · see citing works
- Authors
- Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J.
- Affiliations
- University of Eastern Finland (FI)
- EPID Research Oy, Espoo, Finland
- Corresponding author
- Tiihonen, Jari
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-12-20
- Volume
- 44
- Issue
- 6
- Pages
- 1381-1387
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6192491
- OpenAlex
- W2776169777
- Cited by
- 153
- References
- 15
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 16 · 2023: 16 · 2022: 25 · 2021: 35 · 2020: 21 · 2019: 21 · 2018: 7
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Schizophrenia Bulletin (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UEF eRepo (University of Eastern Finland) (submittedVersion, cc-by-nc)
- Funders
- Finnish Ministry of Social Affairs
- Niuvanniemi Hospital
- Eli Lilly (F1D-HL-0341)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs
- MeSH terms
- Paliperidone Palmitate, Olanzapine, Adult, Aged, Clozapine, Female, Finland, Flupenthixol, Follow-Up Studies, Humans, Male, Middle Aged, Patient Readmission, Perphenazine, Schizophrenia, Antipsychotic Agents, Incidence, Prevalence, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
